First, they design bacteria that can migrate to and colonize solid tumours to deliver synthetic antigens. Then, they generate CAR-T cells that recognize these antigens and lyse tumour cells.

Researchers at Columbia University have developed a probiotic-guided chimeric antigen receptor (CAR)-T platform that uses engineered bacteria to infiltrate and produce synthetic antigen targets ...

Gut microbiome analysis of patients with multiple myeloma receiving idecabtagene vicleucel (ide-cel) therapy revealed specific bacterial species ... to improve CAR T outcomes....Exploring these ...